The State of Diabetes Research in America
ClinicalTrials.gov, the federal registry maintained by the National Institutes of Health, currently lists thousands of recruiting diabetes studies you can filter by state, diabetes type, and age. That sounds encouraging, yet most patients never open the database. Three barriers keep them on the sidelines.
Eligibility confusion tops the list. Every protocol publishes inclusion and exclusion criteria that read like a legal contract. A type 2 study may require a diagnosis at least 180 days old, a stable oral medication routine, and no prior use of GLP-1 drugs. Many people skim the fine print, assume they do not qualify, and never ask.
The fear of the unknown runs just as deep. Terms like "investigational drug" and "randomization" trigger understandable hesitation. What helps to know: every study in the registry has passed review by an independent ethics board, informed consent is a conversation rather than a signature, and participants can withdraw at any point without consequence.
Money worries round out the trio. A stubborn myth says trials are expensive. In reality, the investigational treatment and study-related procedures are covered by the sponsor. Compensation for time, travel, and inconvenience is routine, not rare.
What Kinds of Studies Are Recruiting in 2026
The current pipeline is unusually active on both sides of the disease.
For type 1 diabetes, islet transplantation recently received regulatory approval in the United States for adults with recurrent severe hypoglycemia. Academic centers including the University of Pennsylvania, the University of Miami, the University of Minnesota, and City of Hope in Duarte, California, continue to refine the procedure through clinical trials. Automated insulin delivery studies are also recruiting in cities such as Los Angeles and Boston, testing algorithms that pair wearable pumps with continuous glucose monitors.
For type 2 diabetes, the GLP-1 drug class dominates. Phase 3 studies are comparing semaglutide and tirzepatide across different patient groups, including people with cardiovascular concerns and those managing excess weight alongside diabetes. Novo Nordisk's AMAZE 2 study, testing an injectable medicine for weight loss in type 2 diabetes, is actively recruiting at sites from Birmingham, Alabama, to Spartanburg, South Carolina, and Chattanooga, Tennessee.
| Trial Category | Example Programs | Coverage & Typical Compensation | Best Fit For | Advantages | Key Challenges |
|---|
| GLP-1 medication studies | AMAZE 2 (Novo Nordisk) | Study drug covered; shorter studies commonly pay $150-$400, fuller protocols $325-$475 | Adults with type 2 diabetes and excess weight | Early access to emerging therapies, close medical supervision | Requires stable oral meds; excludes prior GLP-1 use |
| Islet transplantation | University of Chicago, Minnesota, Miami programs | Procedures covered; travel support varies by site | Type 1 adults with severe hypoglycemia or hypoglycemia unawareness | Potential to reduce insulin dependence | Immunosuppression risks; strict eligibility |
| Automated insulin delivery | Device studies in Boston and Los Angeles | Device and supplies covered; stipends for data uploads | Type 1 patients on intensive insulin therapy | Refined glucose control through real-world data | Training time and frequent uploads |
| Observational registries | T1D Exchange | Minimal compensation, typically small stipends | Anyone with diabetes | Low commitment, advances research | No direct treatment benefit |
What Participation Actually Looks Like
Expect a screening visit first. Researchers will review your medical history, run labs, and check your A1c against the protocol's targets. If you pass, you will receive the informed consent document. Read it slowly. Ask what happens if you miss a visit, who to call between appointments, and whether your regular doctor will receive updates.
Study visits vary by protocol. A GLP-1 trial might ask for monthly clinic check-ins with blood work; an automated insulin delivery study may require more frequent data uploads and device training. Most coordinators work around your schedule, and many sites offer evening or weekend appointments.
One point participants often overlook: trials monitor more closely than standard care. You will see a research team regularly, get lab results explained, and receive a direct line to someone who knows your case. For people who have felt rushed through ordinary office visits, that level of attention is frequently the most valued part of the experience.
What Trials Pay and What They Cover
Compensation is meant to cover inconvenience, time off work, and travel, not to replace a paycheck. The amounts vary with visit frequency and study length. Verified listings show GLP-1 focus groups paying $150 to $400 per session, while fuller protocols in the PolicyLab clinical trial directory pay $325 to $475 in electronic payment for the full commitment, typically spanning initial screenings, bi-weekly check-ins, and a final assessment.
A six-month study with monthly visits will pay differently than a two-year trial with quarterly visits. Ask the coordinator for a payment schedule before you consent, and confirm how you will be paid, whether by check, electronic transfer, or reloadable card.
Regional Resources Worth Knowing
The AMAZE 2 trial illustrates how geographically spread diabetes research has become. Recruiting sites include the University of Alabama at Birmingham; Headlands Research in Escondido and Diablo Clinical Research in Walnut Creek, California; Jacksonville Center for Clinical Research and the Florida Institute for Clinical Research in Orlando; the International Diabetes Center in Minneapolis; Southgate Medical Group near Buffalo, New York; Spartanburg Medical Research in South Carolina; and the research network in Chattanooga, Tennessee. The sponsor's trial line, (+1) 866-867-7178, connects you with coordinators at these locations.
Islet transplant candidates have fewer options but clearer ones. The University of Chicago program, reachable at 773-702-2504, is recruiting adults with "brittle" type 1 diabetes who meet strict hypoglycemia criteria. Similar programs run at the University of Minnesota and the University of Miami.
If you prefer to search independently, start with ClinicalTrials.gov and filter by condition, state, and recruitment status. The site's Spanish-language version covers the same listings, which matters for the growing number of Hispanic families navigating type 2 diabetes care.
Your Action Plan
- Search ClinicalTrials.gov for diabetes clinical trials near me, using terms like "type 2 diabetes" or "type 1 diabetes" plus your ZIP code.
- Bring the top three studies to your endocrinologist. A doctor who knows your history can flag red flags in the eligibility criteria faster than you can.
- Call the study coordinator directly. Prepare questions about visit frequency, compensation, travel reimbursement, and whether your current medications need to change.
- Review the informed consent form at home, not in the waiting room. Bring a family member to the signing visit if possible.
- Confirm logistics before enrolling: parking validation, lab hours, and how the team shares results with your primary care doctor.
Clinical trials are not for everyone, and that is fine. But for many Americans living with diabetes, a recruiting study represents the most direct path to newer treatments, closer monitoring, and a research team that knows your name. The database is open, the coordinators are one phone call away, and the first step is simply asking a question.
研究の知恵